Showing results (201-210 of 1,584) with videos related to

Sort By:
Pageof 159
Molecular Pharmacology|April 25, 2000
Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitorsH Pelemans, R Esnouf, E De Clercq, et al.
Molecular Pharmacology|November 28, 2000
Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosineB Degrève, R Esnouf, E De Clercq, et al.
Acta Bio-Medica : Atenei Parmensis|September 14, 2020
Inappropriate risk perception for SARS-CoV-2 infection among Italian HCWs in the eve of COVID-19 pandemicMatteo Riccò, Luigi Vezzosi, Federica Balzarini, et al.
Plos One|June 7, 2013
Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1Bart Hoorelbeke, Jie Xue, Patricia J LiWang, et al.
Molecular Pharmacology|May 14, 2008
Simian immunodeficiency virus is susceptible to inhibition by carbohydrate-binding agents in a manner similar to that of HIV: implications for further preclinical drug developmentKatrien O François, Joeri Auwerx, Dominique Schols, et al.
European Journal of Biochemistry|October 15, 1988
Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acidH Nakane, J Balzarini, E De Clercq, et al.
Trends in Parasitology|August 2, 2017
Surface Glycans: A Therapeutic Opportunity for Kinetoplastid DiseasesVíctor M Castillo-Acosta, Jan Balzarini, Dolores González-Pacanowska
Antimicrobial Agents and Chemotherapy|September 25, 2003
Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV actionMiguel Stevens, Christophe Pannecouque, Erik De Clercq, et al.
Molecular Pharmacology|January 15, 2004
Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitorsJoeri Auwerx, Robert Esnouf, Erik De Clercq, et al.
Antiviral Research|July 1, 1991
Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitroJ Neyts, R Snoeck, J Balzarini, et al.
Pageof 159